Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Orally Disintegrating Tablet Market size was over USD 13.8 billion in 2024 and is expected to reach USD 36.7 billion by the end of 2037, registering at a CAGR of 8.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of orally disintegrating tablet is evaluated at USD 14.9 billion.
The demand for patient-friendly drugs, easy-to-swallow, and technological advancement in formulations are steadily amplifying the orally disintegrating tablet market globally. Additionally, continuous research and development are contributing to the taste, stability, and bioavailability of these formulations. As per an article published by the Journal of Young Pharmacists Organization in December 2022, ranolazine as an ODT comprises 35% to 50% bioavailability, 62% protein binding nature, and it gets dissolved in kidneys by 75% and faeces by 25%. Therefore, the presence of such drugs with fast dissolving ability is readily boosting the market.
Moreover, the orally disintegrating tablet market is subjected to expansion based on the rising demand for anti-epileptic drugs. In this regard, a study was conducted by the International League Against Epilepsy Commission on Epidemiology regarding the payer’s pricing of epilepsy treatment which was published by NLM in April 2022. The study included 101 cost-of-illness, both from direct and indirect healthcare cost databases that further included 74 cases from North America and Western Europe. It was reported that the average yearly cost for each person ranged between USD 204 in developing nations to USD 11,432 in developed nations. Also, the overall total price of epilepsy treatment was USD 119.27 billion, thus driving the market expansion.
Orally Disintegrating Tablet Sector: Growth Drivers and Challenges
Growth Drivers
- Diversified therapy applications: The wide application of ODT is prevalent for mental illnesses, epilepsy, and respiratory and nervous disorders, which is highly driving the demand for the orally disintegrating tablet market. The consumption of traditional tablets to overcome these disorders results in dysphagia which affects 6 million adults internationally, out of which 38% suffer for their entire lifetime as stated in the October 2020 article published by NLM. Hence, to combat swallowing difficulty, ODTs are manufactured with analgesics, acetaminophen, or opioids for their use as medications for gastrointestinal conditions as well, thus ensuring market expansion.
- Alternative to traditional tablets: ODTs are a successful alternative to conventional tablets owing to increased bioavailability and rapid absorption capability, positively bolstering the orally disintegrating tablet market growth. As per an article published by NLM in December 2021, levodopa or benzyl hydrazine is a type of ODT to ease patients with Parkinson’s disease. It is formulated with 25.7% microcrystalline cellulose, 6.22% cross-polyvinylpyrrolidone, 5.36% sodium carboxymethyl starch, and 22% mannitol, thus making it an effective alternative to traditional tablets.
Challenges
- Limitation in drug compatibility: Few medications tend to weaken rapidly in the formulation of ODTs owing to the utilization of excipients in high temperature, table matrix, and moisture presence, hindering the growth of the orally disintegration tablet market. Besides, limitation in taste-masking procedures results in the absence of synthesizing medications into over-the-counter formulations. Also, the presence of limited solubility makes the manufacturing process difficult which creates a barrier for the expansion of the market.
- Lack of mechanical strength: Tablets need to survive a drop of several inches during the manufacturing process, and are required to stay intact at the time of packaging and shipping. Therefore, these situations create a challenge for orally disintegrating tablets since there is an absence of durability in comparison to traditional pills. However, the presence of cellulose ensures rigidity, but it dissolves in ODTs, allowing manufacturers to identify fewer sturdy alternatives. All these factors negatively imapct the orally disintegrating tablet market, thus a potential restraint for its upliftment.
Orally Disintegrating Tablet Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.5% |
|
Base Year Market Size (2024) |
USD 13.8 billion |
|
Forecast Year Market Size (2037) |
USD 36.7 billion |
|
Regional Scope |
|
Orally Disintegrating Tablet Segmentation
Application (CNS Disease, Gastrointestinal Disease, CVS Disease)
CNS disease segment is set to dominate orally disintegrating tablet market share of around 49.8% by the end of 2037, based on the application segment. The occurrence of neurodegenerative diseases, mental disorders, and neurological illnesses falls under the category of central nervous system disorders. According to the March 2024 WHO report, more than 1 in 3 people are affected with neurological conditions and over 80% of neurological deaths take place in developing nations. To combat this, Tascenso ODT is a useful drug that prevents the crossing of the blood-brain barrier into the central nervous system, as stated in the 2024 National Multiple Sclerosis Society Organization article.
Type (Anti-Psychotics Drug, Anti-Epileptics Drug)
In orally disintegrating tablet market, anti-psychotics drug segment is expected to dominate revenue share of around 46.5% by the end of 2037. Anti-psychotic medication operates by fluctuating brain chemistry to assist in reducing psychotic symptoms such as disordered thinking, delusions, and hallucinations. In this regard, Research Nester estimated the global anti-psychotic drugs market to increase at a rate of 5.7% along with a valuation of USD 35.8 billion by 2037. Besides, as per the September 2022 WHO report, nearly 15% of the global working population suffers from mental disorders, and this costs the international economy USD 1 trillion every year. Therefore, to keep a check on such medical situations, the overall market is expected to amplify effectively.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportOrally Disintegrating Tablet Industry - Regional Synopsis
North America Market Analysis
North America orally disintegrating tablet market is predicted to account for revenue share of around 41.3% by 2037. Orally disintegrating tablets are readily available in the region to help patients get rid of swallowing. Besides, the region is subjected to increased long-term conditions such as the central nervous system, heart disease, and diabetic disorders. As per the February 2024 CDC report, nearly 42% of the population suffers from 2 or more chronic disorders, and 12% experience at least 5 such disorders. In addition, chronic conditions have a significant effect on US healthcare with 90% of the yearly USD 4.1 trillion healthcare expenditure credited to managing and treating chronic diseases and mental health conditions.
The U.S. orally disintegrating tablet market is gaining traction since pharmaceutical organizations are initiating investments in collaboration with governmental bodies. For instance, in May 2022, Pfizer planned to make an investment by acquiring Biohaven for USD 11.6 billion. The purpose was to expand Biohaven's oral CGRP franchise to more than USD 6 billion during peak sales. In addition, this investment contributed towards Pfizer’s prevailing plan to add USD 25 billion in risk-adjusted revenues by 2030 through business advancement. Hence, organizational investment like this is a steady factor driving market growth in the country, ultimately resulting in the expansion of pharma businesses.
The orally disintegrating tablet market in Canada is witnessing significant growth owing to the increasing prevalence of different types of orally disintegrating tablets. According to the July 2021 Government of Canada report, ondansetron ODTs have a strength of 4 mg and 8 mg with oral route of administration. Besides, in the September 2022 governmental update, Sanis Health Inc. reported its usage among adults (18 to 64 years of age), pediatrics (less than 18 years), and geriatrics (more than 65 years) to prevent vomiting and nausea. However, its increased dosage can result in headaches and constipation, therefore prescribed consumption is recommended, thus amplifying the market growth.
APAC Market Statistics
The orally disintegrating tablet market in APAC is the fastest-growing region and is poised to witness lucrative growth during the forecast timeline. The region is subjected to a high demand for ODTs in a convenient form for aiding chronic diseases. The older population in the country is on the outlook for easy-to-consume and handy drugs that provide adherence in place of traditional medicines. Moreover, there is a rise in the provision of patient-centric healthcare solutions and local businesses are initiating funding for the manufacturing and production of the latest ODT drugs which is positively boosting the market expansion.
The orally disintegrating tablet market in India is expecting substantial growth since there are advancements in the healthcare industry with generous contributions made by medical companies. For instance, in December 2021, Shilpa Medicare Limited launched PRUCALSHIL (Prucalopride) orally disintegrating strips of 1 mg and 2 mg in the country. It is an exclusive formulation that has been developed for the first time internationally and received approval from the Drug Control General of India. This ODT-based drug has been used for the indicative treatment of chronic constipation in adults in whom laxatives fail to deliver satisfactory relief.
The orally disintegrating tablet market in China is gaining exposure owing to its high prevalence and rapid disintegration effect over regional medicines that are available in an immediate-release dosage form. Besides, in November 2020, Viatris which was formed by Pfizer Upjohn and Mylan, launched a healthcare brand in the country. The purpose was to provide high-quality medicines, forward-looking disease management, and digital health technologies to patients and empower healthy lifestyles. Moreover, this contribution also focused on the evolution of the national health plan ‘Healthy China 2030’ as an essential development strategy. Therefore, with such innovative ideas, the market is expected to flourish in the country.
Companies Dominating the Orally Disintegrating Tablet Landscape
- AstraZeneca plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG, Eli Lily and Company
- Mind Medicine Inc.
- Edenbridge Pharmaceuticals, LLC
Companies dominating the orally disintegrating tablet market are gaining rapid exposure due to strategic partnerships for the effective development of tablets to cater to rapid oral disintegration. For instance, in July 2023, Aneva Group and Galvita entered into a partnership with the objective to expand the development, formulation, and production of oral dosage forms. With Galvita’s specific child- and senior-friendly formulations, there has been provision of better taste masking and higher drug loading than oral dosage forms currently in the market. Thereby, with such contributions from companies, the orally disintegrating tablet market is expected to readily amplify internationally.
Here's the list of some key players:
In the News
- In July 2024, Mind Medicine Inc. stated the issuing of the latest patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide) orally disintegrating tablet.
- In December 2021, Edenbridge Pharmaceuticals, LLC notified the U.S. FDA approval regarding the 505(b)(2) new drug application (NDA) for DARTISLA ODT (glycopyrrolate) orally disintegrating tablets.
Author Credits: Radhika Pawar
- Report ID: 7287
- Published Date: Mar 05, 2025
- Report Format: PDF, PPT
